KDM6A and glioblastoma: Combined treatment with TSA and lomustine has been shown to increase DNA double-strand breaks and enhance lomustine sensitivity, while the KDM6A/B inhibitor GSK-J4 has been reported to sensitize GBM cells to lomustine and etoposide [262, 263].